Formation of functional gap junctions in amniotic fluid-derived stem cells induced by transmembrane co-culture with neonatal rat cardiomyocytes

Amniotic fluid-derived stem cells (AFSC) have been reported to differentiate into cardiomyocyte-like cells and form gap junctions when directly mixed and cultured with neonatal rat ventricular myocytes (NRVM). This study investigated whether or not culture of AFSC on the opposite side of a Transwell membrane from NRVM, allowing for contact and communication without confounding factors such as cell fusion, could direct cardiac differentiation and enhance gap junction formation. Results were compared to shared media (Transwell), conditioned media and monoculture media controls. After a 2-week culture period, AFSC did not express cardiac myosin heavy chain or troponin T in any co-culture group. Protein expression of cardiac calsequestrin 2 was up-regulated in direct transmembrane co-cultures and media control cultures compared to the other experimental groups, but all groups were up-regulated compared with undifferentiated AFSC cultures. Gap junction communication, assessed with a scrape-loading dye transfer assay, was significantly increased in direct transmembrane co-cultures compared to all other conditions. Gap junction communication corresponded with increased connexin 43 gene expression and decreased phosphorylation of connexin 43. Our results suggest that direct transmembrane co-culture does not induce cardiomyocyte differentiation of AFSC, though calsequestrin expression is increased. However, direct transmembrane co-culture does enhance connexin-43-mediated gap junction communication between AFSC

World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections

Peer reviewe

Antepartum management of rhesus alloimmunisation. A literature review

Introducción: la aloinmunización Rh es una enfer-medad frecuente en Colombia pese al uso de inmuno-globulina anti-D (Rho) en los embarazos de alto riesgo. Asimismo, es una condición que requiere la identificación temprana de los factores de riesgo, así como el adecuado tamizaje con el fin de lograr una remisión oportuna a una unidad materno-fetal con experiencia para disminuir las complicaciones fetales y brindar la terapia indicada en caso de ser necesario.Objetivo: revisar la exactitud de los métodos de tamizaje y de diagnóstico temprano, así como también la efectividad de los métodos no invasivos e invasivos de tratamiento.Metodología: se realizó una revisión de la lite-ratura existente de acuerdo con las bases de datos PubMed, EBSCO, Ovid y ProQuest desde el año 2000 hasta el 2008, la cual incluyó artículos de revisión e investigaciones originales. Resultados: la titulación de anticuerpos y el pico de velocidad máximo sistólico de la arteria cerebral media son las herramientas que permiten realizar la evaluación y la identificación de las pacientes en riesgo. El tratamiento incluye transfusión intrauterina y parto oportuno mientras que la prevención con la inmunoglobulina anti-D (Rho) continúa indicada.Conclusión: la aloinmunización Rh aún es una pato-logía de interés en el control de las pacientes obstétricas de bajo y alto riesgo. El conocimiento que se obtenga de la enfermedad permitirá realizar el diagnóstico opor-tuno y, de esta manera, identificar los fetos en riesgo que son susceptibles de terapia intrauterina.Introduction: rhesus alloimmunisation remains a common disease in Colombia in spite of universal immunisation having been implemented with immunoglobulin anti-D (Rho) for all susceptible pregnancies. Rh alloimmunisation is a condition requiring risk factors to be identified, all pregnancies to be suitably screened and timely referral to a maternal foetal medicine unit ensured to minimise foetal complications and provide foetal intervention as necessary. Objective: this review was aimed at summarising the available data to provide the reader with tools helping to improve medical care by reviewing the exactitude of screening methods and early diagnosis and the effectiveness of non-invasive and invasive methods of treatment.Methodology: the literature in PubMed, EBSCO, Ovid and ProQuest databases was reviewed. Original papers, reviews, guidelines and bulletins published between 2000 and 2008 were included. Results: antibody titres and middle cerebral artery Doppler were seen to be the screening tools usually used for identifying haemolytic anaemia in the foetus and neonates in Rh alloimmunisation. Rh alloimmunization treatment included close follow-up, intrauterine transfusion and timely delivery and prevention of Rh alloimmunisation by immunoglobulin anti- D (Rho). Conclusion: knowledge of the disease will lead to early recognition of the risk factors and early diagnosis for identifying foetuses at risk which are susceptible to intrauterine therapy

Serial Intrauterine Transfusions for a Hydropic Fetus with Severe Anemia and Thrombocytopenia Caused by Parvovirus: Lessons Learned

Abstract Introduction Fetal exsanguination is a rare complication of cordocentesis. Successful correction of fetal thrombocytopenia is essential for the reduction of risks. Case Report A 25-year-old, gravida 3, P2-0-0-0-2, was referred at 27 weeks of gestation for evaluation of newly diagnosed nonimmune hydrops secondary to parvovirus infection. Despite the use of ancillary platelet transfusions to correct the severe fetal thrombocytopenia, prolonged bleeding from the cord puncture site still occurred, necessitating five intrauterine transfusions to ultimately correct the fetal anemia. Conclusions The use of a smaller-diameter procedure needle, correction of the fetal thrombocytopenia early in the procedure, and external cord compression with the ultrasound transducer were ultimately successful measures in allowing for minimal loss of transfused red cells from the intravascular compartment

Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010AJOG Global Reports at a Glance

BACKGROUND: Hemolytic disease of the fetus and newborn (HDFN) is mediated by maternal alloantibodies, a consequence of immune sensitization during pregnancy with maternal-fetal incompatibility with ABO, Rhesus factor (Rh), and/or other red blood cell antigens. RhD, Kell, and other non-ABO alloantibodies are the primary cause of moderate to severe HDFN, whereas ABO HDFN is typically mild. HDFN live birth prevalence owing to Rh alloimmunization among newborns in the United States was last estimated to be 106 per 100,000 births in 1986. HDFN live birth prevalence owing to all alloantibodies was estimated to be 817 to 840 per 100,000 in Europe. There is a need for updated prevalence estimates in the United States and a better understanding of disease demographics, severity, and treatments. OBJECTIVE: This study aimed to estimate the live birth prevalence of HDFN and the proportion of severe cases of HDFN in the United States, to describe the associated risk factors, and to compare the clinical outcomes and treatments among healthy newborns, newborns with HDFN, and newborns who are sick without HDFN using a nationally representative hospital discharge database. STUDY DESIGN: In this retrospective, observational cohort study, we used data from the 1996 to 2010 National Hospital Discharge Survey to identify live births, defined by inpatient visits with the newborn flag, with and without a diagnosis of HDFN across 200 to 500 sampled hospitals (≥6 beds) per year. Patient and hospital characteristics, alloimmunization status, disease severity, treatment, and clinical outcomes were evaluated. Frequencies and weighted percentages were calculated for all variables. Logistic regression was used to compare the characteristics between newborns with HDFN and other newborns using odds ratios. RESULTS: Of 480,245 live births identified, 9810 HDFN cases were recorded. When weighted to the United States population, this corresponded to a live birth prevalence of 1695 per 100,000 live births. Compared with other newborns, newborns with HDFN were more likely to be female, Black, living in the South (vs the Midwest or West), and treated at larger (>100 beds) and government-owned hospitals. ABO and Rh alloimmunization accounted for 78.1% and 4.3% of newborns with HDFN, respectively, whereas HDFN caused by other antigens, such as Kell and Duffy, accounted for 17.6% of the cases. Among newborns with HDFN, 22% received phototherapy, 1% received simple transfusions, and 0.5% received exchange transfusions or intravenous immunoglobulin. Newborns affected by HDFN caused by Rh alloimmunization were more likely to require medical interventions, including simple or exchange transfusions, and more likely to be delivered by cesarean delivery. Overall, HDFN was associated with a longer hospital length of stay in the neonatal intensive care unit when compared with healthy and other sick newborns, a higher rate of cesarean delivery, and a higher rate of nonroutine discharge than healthy newborns. CONCLUSION: Overall, the live birth prevalence of HDFN was higher than those previously reported, whereas Rh-induced HDFN live birth prevalence was similar to those previously reported. HDFN live birth prevalence owing to Rh alloimmunization decreased over time, likely because of continued Rh immune globulin prophylaxis. Treatment patterns for newborns with HDFN and the comparative clinical outcomes when compared with healthy newborns confirm the continued clinical needs of this population

Measurement of the Bc−B_c^- meson production fraction and asymmetry in 7 and 13 TeV pppp collisions

International audienceThe production fraction of the Bc- meson with respect to the sum of B- and B¯0 mesons is measured in both 7 and 13 TeV center-of-mass (c.m.) energy pp collisions produced by the Large Hadron Collider (LHC), using the LHCb detector. The rate, approximately 3.7 per mille, does not change with energy, but shows a transverse momentum dependence. The Bc--Bc+ production asymmetry is also measured and is consistent with zero within the determined statistical and systematic uncertainties of a few percent